#162114

Coming soon HCI-047 PDX

Cat. #162114

Coming soon HCI-047 PDX

Cat. #: 162114

Cancer Sub-type: Infiltrating Ductal Carcinoma

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose

Institute: The University of Utah Research Foundation

Primary Citation: Guillen, et al. 2022. Nature Cancer. Feb; 3(2):232-250. PMID: 35221336

Tool Details
Patient Details
Engraftment Details
Handling
Application Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Research area: Breast Cancer
  • Description: Please register your interest through the enquiry button (quote not currently available) Human breast cancer-derived xenograft that retains high fidelity to original tumour and provides valuable resources for drug discovery and precision oncology. This panel of Patient Derived Xenografts provide models for some of the deadliest forms of breast cancer including drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and HER2+ tumours. Sample taken in 2017 from malignant ascites collected from Caucasian female, age 82 at time of collection with a primary diagnosis of IDC;2005. Patient had no previous history of smoking. Metastasis was detected in the lymph node, liver, bone, peritoneum, and pleura. Patient had undergone radiation therapy to the breast 2005, 2010 and had received systemic treatment of Anastrozole 2010-2102; zoledronic acid 2010-?; exemestane 2012-2013; tamoxifen 2013; letrozole 2013-2014; tamoxifen 2014-2015; fulvestrant 2015; megestrol 2015-2016; capecitabine 2016; taxol 2016; trastuzumab 2016; ado-trastuzumab emtansine 2016-2017; trastuzumab, taxol 2017; lapatinib, capecitabine 2017 prior to sample collection. Patient characteristics were as follows - ER status: positive (98%), PR status: positive (80%), HER2 status: negative. PDX characteristics were as follows - ER status: negative, PR status: negative, HER2 status: negative. PDX information: PAM50 subtype tests not done and tests to detect metastasis not done.

Patient Details

  • Cancer type: Breast Cancer
  • Cancer subtype: Infiltrating Ductal Carcinoma
  • Biopsy site: Ascites
  • Gender: Female
  • Patient ethnicity: Caucasian
  • Treatment history: Pretreated: Patient had undergone radiation therapy to the breast 2005, 2010 and had received systemic treatment of Anastrozole 2010-2102; zoledronic acid 2010-?; exemestane 2012-2013; tamoxifen 2013; letrozole 2013-2014; tamoxifen 2014-2015; fulvestrant 2015; megestrol 2015-2016; capecitabine 2016; taxol 2016; trastuzumab 2016; ado-trastuzumab, emtansine 2016-2017; trastuzumab, taxol 2017; lapatinib, capecitabine 2017 prior to sample collection

Engraftment Details

  • Mice passaged: Yes
  • Engraftment site: Cleared mammary fat pad
  • Sample type: Frozen Donor Specimen
  • Host strain: Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799
  • Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.

Handling

  • Initial handling information: Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice NRG. NRG(fresh) time to growth: 4 months to 2 cm
  • Additional notes: Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9

Application Details

  • Genetic data: Whole exome sequencing, SNP array, CNV data and RNA sequence from Guillen et al. 2022 Nature Cancer, is available in NIH database dbGaP under accession number phs002479.v1.p1

References

  • Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946
  • Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637
  • Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007
  • Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602
  • Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134
  • Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336